Related Experiment Video
Updated: May 3, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Update on anti-angiogenic treatment for malignant gliomas
John F de Groot1, Jacob J Mandel
1MD Anderson Cancer Center - University of Texas, Houston, TX, USA.
Abstract:
Malignant gliomas are the most common primary brain tumor found in adults. Unfortunately, the prognosis for these type of tumors remains dismal despite aggressive treatment with surgical resection, radiation and chemotherapy. Therefore, therapeutics aimed at disrupting the angiogenesis of these tumors is being utilized in to improve survival outcomes and quality of life. This paper reviews the history of antiangiogenic agents in malignant gliomas, discusses the FDA approval of bevacizumab as monotherapy in recurrent glioblastoma and the subsequent controversy, and analyzes the most recent newly diagnosed trials of RTOG 0825 and AVAglio. Additionally, the results of the latest trials with antiangiogenic agents and possible biomarkers are reviewed. Multiple questions remain regarding the potential benefit of antiangiogenic treatments in patients with glioblastoma. Future clinical trials should be designed to learn more about these drugs, to optimize their future use.
Insights
Antiangiogenic therapies show limited benefit for malignant gliomas, including glioblastoma. Further research is crucial to optimize the use of these agents and improve patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer biology
- Clinical trials
Background:
- Malignant gliomas are aggressive primary brain tumors with poor prognoses.
- Standard treatments (surgery, radiation, chemotherapy) have limited efficacy.
- Antiangiogenic therapies target tumor blood vessel formation to improve outcomes.
Purpose of the Study:
- To review the history and current status of antiangiogenic agents in malignant gliomas.
- To discuss the FDA approval and controversy surrounding bevacizumab.
- To analyze recent clinical trials and explore potential biomarkers.
Main Methods:
- Review of historical data on antiangiogenic agents.
- Analysis of pivotal clinical trials (RTOG 0825, AVAglio).
- Examination of bevacizumab's efficacy and safety profile.
Main Results:
- Bevacizumab's approval for recurrent glioblastoma remains controversial.
- Recent trials in newly diagnosed patients show mixed results.
- Biomarker identification is ongoing to predict treatment response.
Conclusions:
- The overall benefit of antiangiogenic agents in glioblastoma is still debated.
- Further clinical trials are needed to clarify their role and optimize their use.
- Identifying predictive biomarkers is essential for personalized treatment strategies.
